来那替尼对HER2阳性早期乳腺癌女性健康相关生活质量的影响:随机III期ExteNET试验的纵向分析
国际随机双盲安慰剂对照III期ExteNET试验的纵向分析,2840例完成曲妥珠单抗辅助治疗的HER2阳性早期乳腺癌患者随机接受来那替尼240 mg/天或安慰剂12个月。来那替尼组第1个月总体健康相关生活质量较安慰剂组下降(FACT-B总分调整均差-2.9分,EQ-5D指数-0.02),之后组间差异缩小;除第1个月FACT-B身体健康亚量表外,所有组间差异均小于已报道的重要差异。
要点
- 来那替尼组第1个月总体健康相关生活质量较安慰剂组下降,之后组间差异减小。
- 除第1个月FACT-B身体健康亚量表外,所有组间差异均小于已报道的重要差异。
- FACT-B乳腺癌特异亚量表在来那替尼组第3-9个月显示小幅改善,但均小于重要差异。
核心结论
- 延长辅助来那替尼治疗与治疗第1个月健康相关生活质量的一过性、可逆性下降相关,可能与治疗相关腹泻有关。
- 除第1个月身体健康亚量表外,所有来那替尼相关健康相关生活质量变化均未达到临床意义阈值。
研究设计与样本
- 国际、随机、双盲、安慰剂对照III期ExteNET研究,共纳入2840例完成曲妥珠单抗为基础辅助治疗的HER2阳性早期乳腺癌女性。
- 患者随机接受来那替尼240 mg/天或安慰剂治疗12个月,健康相关生活质量为探索性终点。
- 患者在基线及第1、3、6、9、12个月完成FACT-B和EQ-5D问卷。
- 采用协方差分析比较基线变化,缺失值不进行填补,并采用替代方法进行敏感性分析。
- 健康相关生活质量评分变化超过既往报道的重要差异时视为有临床意义。
主要发现
- 意向治疗人群2840例中,FACT-B可评估2407例(来那替尼组1171例,安慰剂组1236例),EQ-5D可评估2427例(来那替尼组1186例,安慰剂组1241例)。
- 问卷完成率超过85%。
- 来那替尼组第1个月总体健康相关生活质量评分较安慰剂组下降(FACT-B总分调整均差-2.9分,EQ-5D指数-0.02),之后组间差异在后续时间点缩小。
- 除第1个月FACT-B身体健康亚量表外,所有组间差异均小于已报道的重要差异。
- FACT-B乳腺癌特异亚量表在来那替尼组第3-9个月显示小幅改善,但均小于重要差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer. PATIENTS AND METHODS: Women (N = 2840) with early-stage HER2-positive breast cancer who had completed trastuzumab-based adjuvant therapy were randomly assigned to neratinib 240 mg/day or placebo for 12 months. HRQoL was an exploratory end point. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQol 5-Dimensions (EQ-5D) questionnaires at baseline and months 1, 3, 6, 9, and 12. Changes from baseline were compared using analysis of covariance with no imputation for missing values. Sensitivity analyses used alternative methods. Changes in HRQoL scores were regarded as clinically meaningful if they exceeded previously reported important differences (IDs). RESULTS: Of the 2840 patients (intention-to-treat population), 2407 patients were evaluable for FACT-B (neratinib, N = 1171; placebo, N = 1236) and 2427 patients for EQ-5D (neratinib, N = 1186; placebo, N = 1241). Questionnaire completion rates exceeded 85%. Neratinib was associated with a decrease in global HRQoL scores at month 1 compared with placebo (adjusted mean differences: FACT-B total, -2.9 points; EQ-5D index, -0.02), after which between-group differences diminished at later time-points. Except for the FACT-B physical well-being (PWB) subscale at month 1; all between-group differences were less than reported IDs. The FACT-B breast cancer-specific subscale showed small improvements with neratinib at months 3-9, but all were less than IDs. Sensitivity analyses exploring missing data did not change the results. CONCLUSIONS: Extended adjuvant neratinib was associated with a transient, reversible decrease in HRQoL during the first month of treatment, possibly linked to treatment-related diarrhea. With the exception of the PWB subscale at month 1, all neratinib-related HRQoL changes did not reach clinically meaningful thresholds. ClinicalTrials.gov: NCT00878709.
引用
- Delaloge S, Cella D, Ye Y, et al. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol. 2019. PMID: 30689703. doi:10.1093/annonc/mdz016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。